HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis-Reference-Cited by-同舟云学术

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

Published:2011-09-14 Issue:10 Volume:18 Page:e516-e522
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:

Author:

Nkontchou G.,Ziol M.,Aout M.,Lhabadie M.,Baazia Y.,Mahmoudi A.,Roulot D.,Ganne-Carrie N.,Grando-Lemaire V.,Trinchet J.-C.,Gordien E.,Vicaut E.,Baghad I.,Beaugrand M.

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2011.01441.x/fullpdf

Reference32 articles.

1. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis;Piodi;Hepatology,2008

2. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3;Rubbia-Brandt;J Hepatol,2000

3. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation;Jhaveri;J Infect Dis,2008

4. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis;Castéra;Gut,2004

5. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis;Mirandola;Gastroenterology,2006

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognosis associated factors of chronic hepatitis C patients and a case report of resistance-associated substitutions to sofosbuvir-velpatavir treatment;2024-07-02

2. Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy;Exploration of Digestive Diseases;2024-06-18

3. Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review;World Journal of Gastrointestinal Oncology;2024-04-15

4. Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors;Archives of Microbiology;2024-04-15

5. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10